中成药致肝损害47例临床分析

目的：探讨中成药所致药物性肝损害（DILI）的临床特点及预防措施。方法：对2006年1月至2008年12月间我院收治的DILI患者47例进行回顾性研究，分析中成药分类、肝损伤情况以及预防措施。结果：本组服用抗凝调脂药者25例（53．19％），居首位；其次为服用降压扩血管类药物者12倒（25．53％）。口服制荆41例（87．23％），注射液6例（12．77％）。＜60岁组患者出现症状的时间及肝损伤持续时间明显短于≥60岁组患者，两组比较差异具有统计学意义（P＜0．05）。ALT升高45例（95．74％），居首位，其次为AST29例（61．70％）。所有患者经积极治疗均获治愈。结论：中成药所致药物性肝损害临床并非少见，生产企业应严格控制药品质量，同时医生应合理辨症施治，患者严格遵医服用，以最大程度地减少中成药所致的药物性肝损害。

Analysis on Hepatic Lesion Caused by Chinese Patent Medicine

Objective: To investigate the clinical features and prevent measures of drug-induced liver injury caused(DILI)by Chinese patent medicine.Method: 47 cases with DILI who were cured in our hospital from January in 2006 to December in 2008 were reviewed retrospectivly,and the classifications of Chinese patent medicine,states of hepatic lesion and the prevent measures were analysed.Result: There were 25(53.19%) patients who took the anticoagulation drugs,12(25.53%) patients who took the decompaction and expand b...